The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) demonstrated that canakinumab, an IL-1β inhibitor, effectively lowered MACE rates in patients with or without diabetes. Here, IL1B is linked to diabetes mellitus.